Physician profile
Peter R Mcnally
NPI 1013987965
$1,102,902.03
in general payments reported to CMS, 2019-2025
12 companies · $219K in 2025
The $219K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239K · 2020: $41K · 2021: $112K · 2022: $187K · 2023: $105K · 2024: $199K · 2025: $219K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $433K · Travel and Lodging: $83K · Consulting Fee: $4,298 · Food and Beverage: $3,761 · Education: $3.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $432,737.13 |
| Travel and Lodging | $83,483.24 |
| Consulting Fee | $4,297.50 |
| Food and Beverage | $3,761.25 |
| Education | $3.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $311,028.59 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $276,858.81 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $196,108.40 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $119,617.49 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106,168.16 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $28,297.36 | 2025 | Rezdiffra |
| Horizon Therapeutics Plc | $19,225.32 | 2019-2020 | |
| Abbvie INC. | $18,571.44 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $13,729.35 | 2024 | Voquezna |
| Gilead Sciences, INC. | $5,648.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $4,525.00 | 2019-2020 | |
| Celgene Corporation | $3,123.12 | 2022-2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mcnally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.